Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10 + advanced non-small cell lung cancer.
George R BlumenscheinSiddhartha DevarakondaMelissa JohnsonVictor MorenoJustin GainorMartin J EdelmanJohn V HeymachRamaswamy GovindanCarlos BachierBernard Doger de SpévilleMatthew J FrigaultAnthony J OlszanskiVincent K LamNatalie HylandJean-Marc NavenotSvetlana FayngertsZohar WolchinskyRobyn BroadDzmitry BatrakouMelissa M PentonyJoseph P SandersonAndrew GerryDiane MarksJane BaiTom HoldichElliot NorryPaula M FracassoPublished in: Journal for immunotherapy of cancer (2022)
ADP-A2M10 demonstrated an acceptable safety profile and no evidence of toxicity related to off-target binding or alloreactivity. There was persistence of ADP-A2M10 in peripheral blood as well as ADP-A2M10 trafficking into the tumor. Given the discovery that MAGE-A10 and MAGE-A4 expression frequently overlap, this clinical program closed as trials with SPEAR T cells targeting MAGE-A4 are ongoing.